Medy-Tox Past Earnings Performance
Past criteria checks 1/6
Medy-Tox's earnings have been declining at an average annual rate of -6.6%, while the Biotechs industry saw earnings growing at 7.2% annually. Revenues have been growing at an average rate of 5.1% per year. Medy-Tox's return on equity is 1.1%, and it has net margins of 1.9%.
Key information
-6.6%
Earnings growth rate
-7.6%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 5.1% |
| Return on equity | 1.1% |
| Net Margin | 1.9% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Medy-Tox Inc. (KOSDAQ:086900) Surges 37% Yet Its Low P/S Is No Reason For Excitement
Jul 19
Medy-Tox's (KOSDAQ:086900) Anemic Earnings Might Be Worse Than You Think
Mar 31Medy-Tox Inc.'s (KOSDAQ:086900) Prospects Need A Boost To Lift Shares
Feb 27Tread With Caution Around Medy-Tox Inc.'s (KOSDAQ:086900) 0.4% Dividend Yield
Apr 02A Look At Medy-Tox's (KOSDAQ:086900) Share Price Returns
Feb 09
Read This Before Buying Medy-Tox Inc. (KOSDAQ:086900) For Its Dividend
Dec 18Revenue & Expenses Breakdown
How Medy-Tox makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 246,252 | 4,595 | 102,609 | 25,133 |
| 31 Mar 24 | 233,035 | 1,751 | 98,677 | 25,133 |
| 31 Dec 23 | 221,121 | 8,780 | 87,152 | 25,133 |
| 30 Sep 23 | 205,386 | 10,346 | 70,851 | 23,324 |
| 30 Jun 23 | 200,043 | 25,877 | 57,266 | 23,324 |
| 31 Mar 23 | 198,012 | 36,545 | 55,847 | 23,324 |
| 31 Dec 22 | 195,096 | 36,035 | 52,548 | 23,324 |
| 30 Sep 22 | 182,052 | 23,216 | 51,734 | 23,267 |
| 30 Jun 22 | 198,617 | 30,632 | 48,486 | 23,267 |
| 31 Mar 22 | 192,805 | 43,052 | 42,926 | 23,267 |
| 31 Dec 21 | 184,870 | 93,179 | 44,453 | 23,267 |
| 30 Sep 21 | 175,194 | 89,727 | 75,008 | 9,730 |
| 30 Jun 21 | 141,110 | 69,059 | 72,218 | 17,734 |
| 31 Mar 21 | 138,761 | 31,503 | 73,360 | 25,644 |
| 31 Dec 20 | 140,828 | -29,577 | 73,962 | 32,544 |
| 30 Sep 20 | 169,531 | -12,877 | 84,974 | 30,997 |
| 30 Jun 20 | 182,101 | -9,739 | 89,436 | 29,813 |
| 31 Mar 20 | 195,537 | 6,671 | 91,341 | 28,336 |
| 31 Dec 19 | 205,900 | 26,206 | 79,269 | 27,016 |
| 30 Sep 19 | 191,069 | 43,578 | 56,105 | 23,294 |
| 30 Jun 19 | 190,954 | 54,898 | 48,154 | 20,947 |
| 31 Mar 19 | 190,887 | 62,348 | 40,070 | 19,637 |
| 31 Dec 18 | 205,445 | 69,964 | 42,697 | 19,081 |
| 30 Sep 18 | 215,001 | 72,978 | 45,362 | 21,275 |
| 30 Jun 18 | 207,067 | 71,844 | 43,996 | 21,745 |
| 31 Mar 18 | 199,573 | 74,394 | 40,781 | 20,875 |
| 31 Dec 17 | 181,239 | 70,106 | 36,522 | 19,063 |
| 30 Sep 17 | 168,236 | 65,816 | 31,101 | 15,532 |
| 30 Jun 17 | 160,927 | 67,142 | 28,133 | 12,453 |
| 31 Mar 17 | 144,971 | 62,573 | 25,627 | 9,864 |
| 31 Dec 16 | 133,256 | 59,231 | 23,236 | 8,274 |
| 30 Sep 16 | 118,090 | 55,656 | 21,853 | 6,824 |
| 30 Jun 16 | 108,114 | 51,536 | 19,398 | 6,566 |
| 31 Mar 16 | 98,465 | 47,367 | 17,095 | 5,854 |
| 31 Dec 15 | 88,505 | 42,293 | 15,721 | 5,002 |
| 30 Sep 15 | 78,066 | 37,393 | 15,146 | 4,722 |
| 30 Jun 15 | 87,180 | 48,726 | 13,994 | 3,371 |
| 31 Mar 15 | 81,388 | 45,602 | 14,054 | 3,511 |
| 31 Dec 14 | 75,892 | 43,628 | 13,099 | 3,548 |
| 30 Sep 14 | 70,699 | 41,200 | 11,805 | 2,611 |
| 30 Jun 14 | 48,631 | 22,938 | 12,207 | 3,465 |
| 31 Mar 14 | 43,640 | 18,419 | 12,018 | 3,442 |
| 31 Dec 13 | 39,141 | 14,304 | 12,697 | 3,666 |
| 30 Sep 13 | 40,719 | 13,762 | 14,921 | 4,696 |
Quality Earnings: A086900 has high quality earnings.
Growing Profit Margin: A086900's current net profit margins (1.9%) are lower than last year (12.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A086900's earnings have declined by 6.6% per year over the past 5 years.
Accelerating Growth: A086900's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: A086900 had negative earnings growth (-82.2%) over the past year, making it difficult to compare to the Biotechs industry average (6.1%).
Return on Equity
High ROE: A086900's Return on Equity (1.1%) is considered low.